Tumor specific vaccine therapy by fusion cells of dendritic cells and tumor cells

(1)2001：我们检测了转导IL-2基因的脾来源的树突状细胞(DC)与QRsP纤维肉瘤细胞制备的融合细胞对小鼠肺转移模型的预防和治疗作用。我们的结果表明，脾来源的DC与肿瘤细胞的融合细胞免疫能够诱导针对肺转移的预防性和治疗性抗肿瘤免疫，IL-2基因的编码可以提高抗肿瘤效果。(2)2002年：我们检测了两种BRM OK432和PSK对DC功能成熟的影响，并与脂多糖和成熟鸡尾酒(IL-1β，肿瘤坏死因子-α，IL-6和前列腺素E_2)进行了比较。我们的结果表明OK432是一种促进DC功能成熟的GMP级试剂。(3)2003年：我们研究了DC融合疫苗在胃肠道肿瘤患者中的I期临床试验。在获得知情同意后，9名对标准手术和化疗无效的晚期或复发胃肠癌患者参加了这项研究。用聚乙二醇法和电穿孔法将照射后的肿瘤细胞与DC融合。融合疫苗每两周四次皮下注射到腹股沟区域。接种疫苗后，任何患者都没有出现不良反应或自身免疫反应。5名患者的临床反应稳定，4名患者病情恶化。

(1)2001 : We examined the preventive and therapeutic effects of fusion cells prepared from spleen-derived endritic cells (DCs) transduced with the interleukin-2 (IL-2) gene and QRsP fibrosarcoma cells in a mouse lung metastasis model. Our results showed that immunization with fusion cells prepared from spleen-derived DCs and tumor cells is capable of inducing preventive and therapeutic anti-tumor immunity against lung metastasis, and codification by the IL-2 gene may increase anti-tumor efficacy.(2)2002 : We examined the effects of two BRMs OK432 and PSK for the functional maturation of DCs, and compared with that of lipopolysaccharide (LPS) and a maturation cocktail (IL-1 β,TNF-α, IL-6 and PGE2). Our results showed that OK432 is a GMP-grade reagent that promotes functional maturation of DCs.(3)2003 : We studied phase I clinical trial of DC fusion vaccine in patients with gastrointestinal cancer. Nine patients with advanced or recurrent gastrointestinal cancer that was unresponsive to standard surgical therapy and chemotherapy were enrolled in this study after informed consent was obtained. Fusion of irradiated tumor cells and DCs was created by polyethylene glycol and electroporation. The fusion vaccine was injected subcutaneously into the inguinal region four times every two weeks. There were no adverse effects or autoimmune responses after vaccination in any patient. The clinical response was stable in five patients, and disease progression in four patients.